Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L7 like 1 pseudogene 22 (RPL7L1P22) is classified as a processed pseudogene in the human genome[7]. Pseudogenes are DNA sequences similar to known genes that have lost their protein-coding ability or are otherwise no longer expressed in the cell. They are usually formed by retrotransposition or duplication events followed by disabling mutations[6]. RPL7L1P22, like most ribosomal protein pseudogenes, does not produce a functional ribosomal protein product. It is distinct from the functional RPL7 or RPL7L1 genes, which encode components of the large ribosomal subunit important for protein biosynthesis[1][5]. No biological function, disease role, or relevance as a therapeutic target is currently attributed to RPL7L1P22[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 like 1 pseudogene 22 (RPL7L1P22).